2017/18 group forecast
Brief: I'rom Group unit ID Pharma concludes iPS cell generation technology licensing agreement with UK-based Axol Bioscience
2016/17 group forecast
2016/17 parent results
2016/17 group results
2016/17 group forecast
Brief: I'rom Group unit signs license contract with Mayo Clinic on iPS cells
Brief: I'rom Group to fully acquire Ethic Co Ltd via stock swap
9-MTH group results
Brief: I'rom Group buys 61 pct stake in CMAX Clinical Research
Brief: I'rom Group says exercise of warrants
Brief: I'rom Group unit gets patent grant in Japan and U.S. for cells production technology
6-MTH group results
Brief: I'rom Group unit forms business alliance with KKR
Brief: I'rom Group to buy CMAX Pty Ltd from IDT Australia
Q1 group results
Brief: I'rom Group unit announces success in production process of retinal pigment degeneration treatment
Brief: I'rom Group unit ID Pharma to grant technology license to KOHJIN BIO
Brief: I'rom Group unit gets license for improvement of iPS cell preparation technology in China